All In Biotech

Drug Trial Radar · NCT05827796

IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer

A Phase Ib/II, Open-label Clinical Study to Evaluate the Safety, Tolerability and Antitumor Activities of IN10018+Standard Chemotherapy and IN10018+Standard Chemotherapy+KN046 in Subjects With Advanced Pancreatic Cancer

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Dec 8, 2022

Primary completion

Oct 11, 2025

Study completion Dec 31, 2026

Sponsor

Lead sponsor
InxMed (Shanghai) Co., Ltd.Industry
Sponsor type
Industry
First posted
Apr 25, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, open-label, single-arm, phase Ib/II clinical study comprising two phases: dose confirmation phase and dose expansion phase. The objective of the dose confirmation phase is to determine the recommended Phase II dose (RP2D) of IN10018+ standard chemotherapy (albumin-bound paclitaxel + gemcitabine) and IN10018 + KN046 + standard chemotherapy in subjects with advanced pancreatic cancer. The dose expansion phase will further explore the antitumor activities and safety of combination therapy in subjects with advanced pancreatic cancer.

Conditions

  • Pancreatic Cancer

Interventions

  • IN10018Drug

    IN10018 orally once daily at approximately the same time each day, to ensure a dosing interval of approximately 24 hours.

  • Albumin-Bound PaclitaxelDrug

    Albumin-bound paclitaxel will be administered as per the schedule specified in the respective arm.

  • GemcitabineDrug

    Gemcitabine will be administered as per the schedule specified in the respective arm.

  • KN046Drug

    KN046 5 mg/kg on Day 1 of each 21-Day Cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Related Adverse Events (AEs)Time frame: 1 year
  2. To evaluate the objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) in subjects with advanced pancreatic cancer.Time frame: 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Renji Hospital of Shanghai Jiaotong University School of Medicine

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.